ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster

Investors who backed a $50m Series C venture capital round for ARMO BioSciences are betting that the Redwood City, California-based company will be part of a second immuno-oncology wave with pegylated interleukins that are designed to boost the field's first wave of new therapies.